Results 21 to 30 of about 52,891 (241)

Advances in hypertrophic cardiomyopathy: What the cardiologist needs to know

Revista Portuguesa de Cardiologia, 2022
Hypertrophic cardiomyopathy (HCM) is known as the most common genetic heart disease, characterized by otherwise unexplained left ventricular (LV) hypertrophy.
Alexandra Toste
doaj   +1 more source

Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome

Reviews in Cardiovascular Medicine, 2023
Despite considerable interest in the syndrome of acute left ventricular (LV) ballooning, its pathophysiology has remained ill-defined. In this review, we explore observational data describing two etiologies of acute LV ballooning: neurohumoral classic ...
Arushi Singh, Louai Razzouk, Daniele Massera, Mark V. Sherrid   +3 more
doaj   +1 more source

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana, Angelica T. Mejia, Miriam R. Elman, Daniel Kamna, Olives Nguyen, Hailey Volk, Hongya Chen, Ahmad Masri   +7 more
doaj   +1 more source

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

Journal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao, Wen Luo, Jing Hu, Lei Zuo, Jing Wang, Rui Hu, Bo Wang, Lei Xu, Jing Li, Meng Wu, Pan Li, Liwen Liu   +11 more
doaj   +1 more source

Extreme hypertrophic cardiomyopathy [PDF]

Heart, 2003
A 21 year old Jamaican woman with hypertrophic cardiomyopathy (HCM) was referred for sudden death risk assessment. The initial diagnosis of HCM was made at the age of 13 years and mild exertional dyspnoea has occurred since age 15 (New York Heart Association functional class II), but without syncope or chest pain. There is no …
B J, Maron, S A, Casey, A K, Almquist
openaire   +2 more sources

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin   +9 more
doaj   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source

Hypertrophic Obstructive Cardiomyopathy [PDF]

Deutsches Ärzteblatt international, 2019
Hypertrophic cardiomyopathy (HCM) is caused by mutations in a number of genes. Its prevalence is 0.2% to 0.6%.This review is based on publications retrieved by a selective literature search and on the authors' clinical experi- ence.70% of patients with HCM suffer from the obstructive type of the condition, clinically characterized by highly dynamic and
Angelika, Batzner, Hans-Joachim, Schäfers, Konstantin V, Borisov, Hubert, Seggewiß   +3 more
openaire   +2 more sources

Seipin‐Mediated Lipid Droplet Formation in Cardiomyocytes Ameliorates Cardiac Ischemia/Reperfusion Injury

Advanced Science, EarlyView.
Lipid droplets (LDs) protect the heart against lipotoxicity in cardiac ischemia/reperfusion (I/R) injury; however, they are insufficient to prevent cardiomyocyte death. Seipin plays a central role in the insufficient formation of LDs, subsequent lipotoxicity, and myocardial injury during cardiac I/R injury.
Changyun Liu, Junxia Zhang, Yusi Chen, Geng Shen, Yufei Han, Zihao Zhou, Jinxuan Chen, Xuya Kang, Huilin Qu, Jiaxin Duanmu, Haibao Shang, Yingjia Li, Wei Huang, Yan Zhang   +13 more
wiley   +1 more source

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai, Natalie Szpakowski, Albree Tower‐Rader, Barb Bittel, Agostina Fava, Susan Ospina, Bo Xu, Maran Thamilarasan, Amgad Mentias, Nicholas G. Smedira, Zoran B. Popovic   +10 more
doaj   +1 more source